Ann Clin Microbiol 2026;29(3):11. Molecular mechanisms, epidemiology, and clinical implications of macrolide resistance in group A Streptococcus: a narrative review

Table 2. Representative associations between emm types and macrolide resistance determinants in group A Streptococcus
emm typeGeographic settingReported resistance determinant(s)Typical phenotypeRepresentative epidemiological associationRepresentative reference
(first author, year)
emm4Europe, North AmericamefAM phenotypeemm4/ST39 lineage associated with mefA-mediated macrolide resistanceBerbel, 2022 [5];
Silva-Costa, 2015 [6]
emm11Europe, North AmericaermB, often with tet(M)cMLSBemm11/ST403 lineage associated with ermB-mediated macrolide resistanceChochua, 2017 [18]; Silva-Costa, 2015 [6]
emm12East Asia, Europe, North AmericaermB, erm(TR), or mefA depending on lineage and regioncMLSB, iMLSB, or M phenotypeMultiple resistance genotypes reported; ermB-associated resistant emm12 lineages have been prominent in ChinaLi, 2020 [9]; Cai, 2025 [10]; Chochua, 2017 [18]
emm77Europe, North Americaerm(TR); erm(T) reported in some lineagesPredominantly iMLSBResistance genotype varies by clonal background; erm(TR) has been associated with emm77/ST63Silva-Costa, 2015 [6]; Chochua, 2017 [18]
emm92North Americaerm(T), often with tet(M)Predominantly iMLSBStrong association of emm92/ST82 with erm(T) in US invasive GAS surveillanceChochua, 2017 [18]

Associations between emm types and resistance determinants are epidemiological rather than invariant biological characteristics and may differ substantially across geographic regions, study periods, and clonal backgrounds.
Abbreviations: cMLSB, constitutive macrolide-lincosamide-streptogramin B resistance; iMLSB, inducible macrolide-lincosamide-streptogramin B resistance; M phenotype, macrolide efflux phenotype; ST, sequence type.